Stock search

Ticker or company name

AbbVie

ABBV · NYSE · Biotechnology

$294,55Down −0,48 (−0,16%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$521 bn
Div. yield
4,5%
Year to date
+29,1%
52 weeks: $190,75$302,93

Ratio score

72/100
Ratio would consider buying

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

5 ✓ · 3 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM50,454,842,1
Forward P/E18,7—18,7
PEG3,9—4,1
P/S7,95,56,6
EV/EBITDA26,925,928,2
P/FCF27,6—26,0
P/B367,318,09,8

Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 38 analysts

Buy
31
Hold
7
Sell
0

Beat the EPS forecast in 2 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20263,823,82Down −0,1%
Q2 20263,683,65Down −0,7%
Q1 20262,652,65Up +0,2%
Q4 20252,712,71Up +0,2%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue17,4 bn17,0 bn15,0 bn16,6 bn15,8 bn15,4 bn13,3 bn15,1 bn14,5 bn14,5 bn12,3 bn14,3 bn
EPS2,372,030,391,020,100,520,72−0,020,880,770,770,46
Margin24,2%21,3%4,6%10,9%1,2%6,1%9,6%−0,1%10,8%9,5%11,1%5,7%
FCF7,31 bn3,11 bn3,56 bn4,89 bn6,64 bn4,88 bn1,40 bn6,76 bn5,20 bn2,03 bn3,85 bn4,55 bn

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $30,8 m.

NameAmountSharesPrice
stewart jeffrey ryan9 Nov 2026 · sale$11,9 m40 619$293,60
donoghoe nicholas14 Aug 2026 · sale$8,18 m32 710$250,00
purdue david ryan4 Mar 2026 · sale$1,22 m5 230$233,56
siatis perry c2 Mar 2026 · sale$611 6762 600$235,26
siatis perry c2 Mar 2026 · sale$2,41 m10 291$234,66
siatis perry c2 Mar 2026 · sale$1,35 m5 777$233,51
siatis perry c25 Feb 2026 · sale$5,15 m22 381$230,00

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Biotechnology
Exchange
NYSE
Country
US
IPO date
2 Jan 2013

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
AMGNAmgen$462,3267would watch26,8+8,2%24,1%
GILDGilead Sciences$167,5825would not consider—+6,5%−12,5%
VRTXVertex Pharmaceuticals$537,7972would consider33,7+10,5%30,7%
REGNRegeneron Pharmaceuticals$952,4067would watch20,5+18,6%28,5%
MRNAModerna$215,2722would not consider—+13,1%−110,5%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.